Mp73-07 oncological and functional outcomes of men undergoing salvage whole gland cryoablation of the prostate

You have accessJournal of UrologyCME1 Apr 2023MP73-07 ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF MEN UNDERGOING SALVAGE WHOLE GLAND CRYOABLATION OF THE PROSTATE Wei Phin Tan, New York, Ny, Srinath Kotamarti, Emily Chen, Rachael Mahle, Alexandria Ayala, Zoe Michael, Denis Seguier, and Thomas Polascik Wei Phin TanWei Phin Tan More articles by this author , New YorkNew York More articles by this author , Ny Ny More articles by this author , Srinath KotamartiSrinath Kotamarti More articles by this author , Emily ChenEmily Chen More articles by this author , Rachael MahleRachael Mahle More articles by this author , Alexandria AyalaAlexandria Ayala More articles by this author , Zoe MichaelZoe Michael More articles by this author , Denis SeguierDenis Seguier More articles by this author , and Thomas PolascikThomas Polascik More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003341.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We aim to report the oncological and functional outcomes in men who were treated with salvage whole gland cryoablation (SWGC) of the prostate for radiation resistant/recurrent prostate cancer. METHODS: We retrospectively reviewed our prospectively collected cryosurgery database between January 2002 and September 2019 for men who were treated with SWGC of the prostate at a tertiary referral center. Primary outcome includes biochemical recurrence-free survival (BRFS) based off the Phoenix criteria. Secondary outcomes include metastasis-free survival (MFS), cancer-specific survival (CSS), and adverse events. Kaplan-Meier and multivariable Cox regression analyses were performed using a landmark starting at 3 months of follow-up. RESULTS: A total of 110 men with biopsy-proven radiation-resistant prostate cancer were included in the study. Median follow-up was 71 months (interquartile range [IQR]: 42.3 – 116). BRFS at 2 years and 5 years were 81% and 71%, respectively. On multivariable Cox proportionate hazards analysis, we found that a precryoablation PSA of 4-10 ng/dL (HR 2.10, 95% CI 1.00 – 4.41) and PSA of>10 ng/dL (HR 4.26, 95% CI 1.35 – 13.40) to be associated with a lower BRFS. A higher PSA nadir was also associated with a lower BRFS. All patients with a PSA nadir of>0.5 eventually developed biochemical recurrence. Median IIEF-5 scores pre-cryoablation and post-cryoablation were 5 (IQR 1 – 15.5) and 1 (IQR 1 – 4), respectively. Stress urinary incontinence, strictly defined as requiring the use of any pads post-treatment, assessed at 3 month and 12 months were 5% and 9%, respectively. Clavien-Dindo ≥3 adverse events occurred in 3 (2.7%) patients. CONCLUSIONS: In the appropriate clinical context, SWGC can achieve excellent oncological outcomes with minimal adverse events in men with radiation-resistant localized prostate cancer. Source of Funding: NA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1037 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Wei Phin Tan More articles by this author New York More articles by this author Ny More articles by this author Srinath Kotamarti More articles by this author Emily Chen More articles by this author Rachael Mahle More articles by this author Alexandria Ayala More articles by this author Zoe Michael More articles by this author Denis Seguier More articles by this author Thomas Polascik More articles by this author Expand All Advertisement PDF downloadLoading ...